UnitedHealth Group stock plunged on rising medical costs, leadership shifts, and a DOJ probe, plus 2025 guidance withdrawal.

These initiatives are integral to market access, as companies recognise that their societal impact can significantly influence their ability to bring new therapies to patients. As healthcare ...